Forest Sues Glenmark Over Generic Fibromyalgia Treatment

Law360, New York (February 7, 2014, 5:32 PM EST) -- Forest Laboratories Inc. hit Glenmark Generics Inc. USA with a lawsuit in Delaware federal court on Thursday, the latest in a series of complaints the company has filed alleging that proposed generic versions of its fibromyalgia treatment Savella infringe three of its patents.

New York-based Forest claims in the suit that Glenmark's abbreviated new drug application for the sale of milnacipran hydrochloride in 12.5, 25, 50 and 100 milligram dosage strengths would infringe on several patents it holds that indicate methods for treating fibromyalgia. Those patents are not...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.